Kazia Therapeutics (KZIA) Earnings Analysis

Kazia Therapeutics (KZIA) next reports earnings on 2026-09-04, consensus EPS -0.69729 USD. Last quarter (2026-03-16) it missed with EPS -0.57887 USD vs -0.00697 USD est (-8205.2%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E -2.01.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does KZIA next report earnings?

Next earnings date2026-09-04
Consensus EPS estimate-0.69729 USD
Revenue estimate0.00B

KZIA earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-16-0.57887 USD-0.00697 USD-8205.2%Miss
2025-06-29-4.18368 USD-0.00653 USD-63968.6%Miss
2025-05-28-7.60928 USD-10.76188 USD+29.3%Beat
2024-11-19-20.81247 USD-15 USD-38.7%Miss

Beat rate: 1/4 (25%) over reported quarters with consensus data.

KZIA valuation and analyst view

Trailing P/E-2.01
Trailing EPS-7.13787 USD
Price / book1.40
Dividend yield0.00%
Market cap0.02B
Analyst consensusBuy (3 buy / 0 hold / 0 sell)
Avg price target33 USD

Related research pages

Frequently asked questions

When is Kazia Therapeutics (KZIA)'s next earnings date?

Kazia Therapeutics is next scheduled to report on 2026-09-04, with a consensus EPS estimate of -0.69729 USD and revenue estimate of 0.00B.

Did KZIA beat earnings last quarter?

In its 2026-03-16 report, KZIA posted EPS of -0.57887 USD versus a -0.00697 USD estimate — a miss of 8205.2%.

What is KZIA's earnings track record?

Over the last 4 reported quarters with consensus data, KZIA beat estimates 1 times (25%).

What is KZIA's current P/E ratio and EPS?

KZIA trades at a trailing P/E of -2.01 on trailing EPS of -7.137872200782842 USD.

What do analysts rate KZIA?

Analyst consensus is "Buy" across 3 ratings (0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 33 USD.